Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial

Background: The clinical benefits of cytochrome P450 (CYP) 2C19 genotype-guided antiplatelet therapy in Asians remain unclear. In this study, we aimed to investigate the clinical outcomes of pharmacogenomic antiplatelet therapy in Chinese patients.Methods: Patients with acute coronary syndrome plann...

Full description

Bibliographic Details
Main Authors: Xiujin Shi, Yunnan Zhang, Yi Zhang, Ru Zhang, Baidi Lin, Jialun Han, Wenzheng Li, Zhenwei Fang, Jialin Yan, Yifan Wang, Ze Zheng, Yuan Lv, Yang Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
CYP2C19
personalized antiplatelet therapy
ticagrelor
clopidogrel
acute coronary syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.676954/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2021.676954/full

Similar Items